Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase 660,000 Ordinary Shares

Andrew R. Allen, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 660,000 ordinary shares on July 1, 2024.

Summary

• On July 1, 2024, Andrew R. Allen, a director of Adaptimmune Therapeutics PLC, filed a Form 4 indicating a change in beneficial ownership.
• Allen acquired options to purchase 660,000 ordinary shares of Adaptimmune Therapeutics PLC.
• The exercise price of the options is $0.16 per share, converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00.
• The options are exercisable from July 1, 2025, and expire on July 1, 2034.
• Following the transaction, Allen directly owns options to purchase 660,000 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a director's acquisition of stock options. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such transactions can provide insights into management's perspective on the company's prospects.

Stakeholder Impact

• The acquisition of options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates